Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis

L. W. Torley, W. C. Pickett, M. L. Carroll, C. A. Kohler, R. E. Schaub, A. Wissner, S. Q. DeJoy, A. L. Oronsky, S. S. Kerwar

Research output: Contribution to journalArticle

Abstract

The effect of CL 184,005, a potent and specific platelet-activating factor antagonist, has been examined in a variety of animal models relevant to gram- negative bacterial sepsis. Pretreatment of mice with CL 184,005 protected them from the lethal effects of platelet-activating factor. When rats or primates rendered hypotensive with endotoxin were treated with CL 184,005, blood pressure was normalized. Pretreatment of rats with CL 184,005 protected them from the gastrointestinal lesions induced by endotoxin. Pretreatment of rats and mice with CL 184,005 protected them from the lethal effects of endotoxin. Plasma tumor necrosis factor levels in endotoxin-treated mice were lower when the mice were pretreated with CL 184,005. These observations suggest that CL 184,005 may be potentially useful in the treatment of gram- negative bacterial sepsis, and the agent is undergoing clinical evaluation.

Original languageEnglish (US)
Pages (from-to)1971-1977
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number9
StatePublished - 1992
Externally publishedYes

Fingerprint

Platelet Activating Factor
Sepsis
Animal Models
Endotoxins
CL 184005
Primates
Tumor Necrosis Factor-alpha
Blood Pressure

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Torley, L. W., Pickett, W. C., Carroll, M. L., Kohler, C. A., Schaub, R. E., Wissner, A., ... Kerwar, S. S. (1992). Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrobial Agents and Chemotherapy, 36(9), 1971-1977.

Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. / Torley, L. W.; Pickett, W. C.; Carroll, M. L.; Kohler, C. A.; Schaub, R. E.; Wissner, A.; DeJoy, S. Q.; Oronsky, A. L.; Kerwar, S. S.

In: Antimicrobial Agents and Chemotherapy, Vol. 36, No. 9, 1992, p. 1971-1977.

Research output: Contribution to journalArticle

Torley, LW, Pickett, WC, Carroll, ML, Kohler, CA, Schaub, RE, Wissner, A, DeJoy, SQ, Oronsky, AL & Kerwar, SS 1992, 'Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis', Antimicrobial Agents and Chemotherapy, vol. 36, no. 9, pp. 1971-1977.
Torley, L. W. ; Pickett, W. C. ; Carroll, M. L. ; Kohler, C. A. ; Schaub, R. E. ; Wissner, A. ; DeJoy, S. Q. ; Oronsky, A. L. ; Kerwar, S. S. / Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. In: Antimicrobial Agents and Chemotherapy. 1992 ; Vol. 36, No. 9. pp. 1971-1977.
@article{012f4cc43fb04d189a38ea2e7aa5527d,
title = "Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis",
abstract = "The effect of CL 184,005, a potent and specific platelet-activating factor antagonist, has been examined in a variety of animal models relevant to gram- negative bacterial sepsis. Pretreatment of mice with CL 184,005 protected them from the lethal effects of platelet-activating factor. When rats or primates rendered hypotensive with endotoxin were treated with CL 184,005, blood pressure was normalized. Pretreatment of rats with CL 184,005 protected them from the gastrointestinal lesions induced by endotoxin. Pretreatment of rats and mice with CL 184,005 protected them from the lethal effects of endotoxin. Plasma tumor necrosis factor levels in endotoxin-treated mice were lower when the mice were pretreated with CL 184,005. These observations suggest that CL 184,005 may be potentially useful in the treatment of gram- negative bacterial sepsis, and the agent is undergoing clinical evaluation.",
author = "Torley, {L. W.} and Pickett, {W. C.} and Carroll, {M. L.} and Kohler, {C. A.} and Schaub, {R. E.} and A. Wissner and DeJoy, {S. Q.} and Oronsky, {A. L.} and Kerwar, {S. S.}",
year = "1992",
language = "English (US)",
volume = "36",
pages = "1971--1977",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis

AU - Torley, L. W.

AU - Pickett, W. C.

AU - Carroll, M. L.

AU - Kohler, C. A.

AU - Schaub, R. E.

AU - Wissner, A.

AU - DeJoy, S. Q.

AU - Oronsky, A. L.

AU - Kerwar, S. S.

PY - 1992

Y1 - 1992

N2 - The effect of CL 184,005, a potent and specific platelet-activating factor antagonist, has been examined in a variety of animal models relevant to gram- negative bacterial sepsis. Pretreatment of mice with CL 184,005 protected them from the lethal effects of platelet-activating factor. When rats or primates rendered hypotensive with endotoxin were treated with CL 184,005, blood pressure was normalized. Pretreatment of rats with CL 184,005 protected them from the gastrointestinal lesions induced by endotoxin. Pretreatment of rats and mice with CL 184,005 protected them from the lethal effects of endotoxin. Plasma tumor necrosis factor levels in endotoxin-treated mice were lower when the mice were pretreated with CL 184,005. These observations suggest that CL 184,005 may be potentially useful in the treatment of gram- negative bacterial sepsis, and the agent is undergoing clinical evaluation.

AB - The effect of CL 184,005, a potent and specific platelet-activating factor antagonist, has been examined in a variety of animal models relevant to gram- negative bacterial sepsis. Pretreatment of mice with CL 184,005 protected them from the lethal effects of platelet-activating factor. When rats or primates rendered hypotensive with endotoxin were treated with CL 184,005, blood pressure was normalized. Pretreatment of rats with CL 184,005 protected them from the gastrointestinal lesions induced by endotoxin. Pretreatment of rats and mice with CL 184,005 protected them from the lethal effects of endotoxin. Plasma tumor necrosis factor levels in endotoxin-treated mice were lower when the mice were pretreated with CL 184,005. These observations suggest that CL 184,005 may be potentially useful in the treatment of gram- negative bacterial sepsis, and the agent is undergoing clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0026699705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026699705&partnerID=8YFLogxK

M3 - Article

C2 - 1416889

AN - SCOPUS:0026699705

VL - 36

SP - 1971

EP - 1977

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

ER -